65P Preliminary Results of a Phase II Multicenter, Open-Label Study of Fruquintinib Monotherapy As Third-Line Treatment in Advanced Pancreatic Cancer
ESMO Open（2024）
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined